Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL

Journal of Neurochemistry

Volumn 106, Issue 6, 2008, Pages 2436-2448

  Rieger, Johannes ^a,b   Lemke, Dieter ^c   Maurer, Gabriele ^a,b   Weiler, Markus ^c   Frank, Brigitte ^a   Tabatabai, Ghazaleh ^a   Weller, Michael ^a,d   Wick, Wolfgang ^a,c,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Dr Senckenberg's Institute for Neurooncology   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Department of Neurooncology ^*  (Germany)

Author keywords

Apo2 ligand; Apoptosis; Caspases; Enzastaurin; Glioma initiating cells; Glycogen synthase kinase 3

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYTOCHROME C; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN S6; S6 KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 50849095153     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05586.x     Document Type: Article

References (36)

1. Ashkenazi A., Pai R. C., Fong S. et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155 162.
2. Baltuch G. H. Yong V. W. (1996) Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Res. 710, 143 149.
3. Carducci M. A., Musib L., Kies M. S. et al. (2006) Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. 24, 4092 4099.
4. Couldwell W. T., Hinton D. R., He S., Chen T. C., Sebat I., Weiss M. H. Law R. E. (1994) Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett. 345, 43 46.
5. Cross D. A., Alessi D. R., Cohen P., Andjelkovich M. Hemmings B. A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785 789.
6. Esteller M., Garcia-Foncillas J., Andion E. et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350 1354.
7. Gilbertson R. J. Rich J. N. (2007) Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7, 733 736.
8. Goode N., Hughes K., Woodgett J. R. Parker P. J. (1992) Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J. Biol. Chem. 267, 16878 16882.
9. Graff J. R., McNulty A. M., Hanna K. R. et al. (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65, 7462 7469.
10. Gutcher I., Webb P. R. Anderson N. G. (2003) The isoform-specific regulation of apoptosis by protein kinase C. Cell. Mol. Life Sci. 60, 1061 1070.
11. Hemmati H. D., Nakano I., Lazareff J. A., Masterman-Smith M., Geschwind D. H., Bronner-Fraser M. Kornblum H. I. (2003) Cancerous stem cells arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA 100, 15178 15183.
12. Igney F. H. Krammer P. H. (2002) Death and anti-death: tumour resistance to apoptosis. Nature Rev. 2, 277 288.
13. Jane E. P. Pollack I. F. (2008) The heat shock protein antagonist potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Lett. 268, 46 55.
14. Keyes K. A., Mann L., Sherman M., Galbreath E., Schirtzinger L., Ballard D., Chen Y. F., Iversen P. Teicher B. A. (2004) LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol. 53, 133 140.
15. Lee K. W., Kim S. G., Kim H. P. et al. (2008) Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 68, 1916 1926.
16. Li H., Zhu H., Xu C. J. Yuan J. (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491 501.
17. Moreau A. S., Jia X., Ngo H. T. et al. (2007) Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 109, 4964 4972.
18. Murat A., Migliavacca E., Gorlia T. et al. (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26, 3015 3024.
19. Okhrimenko H., Lu W., Xiang C., Hamburger N., Kazimirsky G. Brodie C. (2005) Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res. 65, 7301 7309.
20. Podar K., Raab M. S., Zhang J. et al. (2007) Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 109, 1669 1677.
21. Querfeld C., Rizvi M. A., Kuzel T. M., Guitart J., Rademaker A., Sabharwal S. S., Krett N. L. Rosen S. T. (2006) The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J. Invest. Dermatol. 126, 1641 1647.
22. Rademaker-Lakhai J. M., Beerepoot L. V., Mehra N. et al. (2007) Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin. Cancer Res. 13, 4474 4481.
23. Rieger J., Frank B., Weller M. Wick W. (2007) Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. Cell. Physiol. Biochem. 20, 23 34.
24. Rizvi M. A., Ghias K., Davies K. M., Ma C., Weinberg F., Munshi H. G., Krett N. L. Rosen S. T. (2006) Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol. Cancer Ther. 5, 1783 1789.
25. Robertson M. J., Kahl B. S., Vose J. M. et al. (2007) Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 25, 1741 1746.
26. da Rocha A. B., Mans D. R., Regner A. Schwartsmann G. (2002) Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 7, 17 33.
27. Shamji A. F., Nghiem P. Schreiber S. L. (2003) Integration of growth factor and nutrient signaling: implications for cancer biology. Mol. Cell 12, 271 280.
28. Steinbach J. P., Wolburg H., Klumpp A., Probst H. Weller M. (2003) Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ. 10, 823 832.
29. Svendsen C. N., ter Borg M. G., Armstrong R. J., Rosser A. E., Chandran S., Ostenfeld T. Caldwell M. A. (1998) A new method for the rapid and long term growth of human neural precursor cells. J. Neurosci. Methods 85, 141 152.
30. Tabatabai G., Frank B., Wick A. et al. (2007) Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann. Neurol. 61, 153 161.
31. Teicher B. A., Alvarez E., Menon K., Esterman M. A., Considine E., Shih C. Faul M. M. (2002) Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother. Pharmacol. 49, 69 77.
32. Uhl M., Aulwurm S., Wischhusen J. et al. (2004) SD-208, a novel TGF-β receptor I antagonist, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 954 961.
33. Van den Bent M. J., Brandes A., Sampling R. et al. (2007) Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM). J. Clin. Oncol. 25, 18S.
34. Wagenknecht B., Schulz J. B., Gulbins E. Weller M. (1998) Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death Differ. 5, 894 900.
35. Yamasaki F., Hama S., Yoshioka H., Kajiwara Y., Yahara K., Sugiyama K., Heike Y., Arita K. Kurisu K. (2003) Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line. Cancer Chemother. Pharmacol. 51, 271 283.
36. Yoshiji H., Kuriyama S., Ways D. K. et al. (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59, 4413 4418.